WAYNE, Pa.--(BUSINESS WIRE)--July 13, 2006--Covalent Group, Inc. (Nasdaq: CVGR - News), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, today announced the signing of two new business contracts in cardiovascular disease that have an aggregate value of $1.5 million. Covalent will provide consulting services and clinical operations support on both of these early phase clinical trials, which are offering advanced therapeutic approaches to patients with severe heart failure.
